Powered by lexis nexis

Revive Therapeutics Appoints Dr. Scott Friedman, MD, as Scientific Advisor for Cannabinoid-Based Therapeutics Targeting Liver Diseases

Mar 22, 2017 - Marketwired
Board and Executive Moves

TORONTO, ONTARIO--(Marketwired - March 22, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that Dr. Scott Friedman, M.D., will join the Company as a Scientific Advisor for cannabinoid-based therapeutics targeting liver diseases.

"I am pleased that Dr. Friedman has joined Revive to assist with adva...